LivaNova (LIVN) – Investment Analysts’ Recent Ratings Updates

A number of firms have modified their ratings and price targets on shares of LivaNova (NASDAQ: LIVN) recently:

• 12/22/2025 – LivaNova had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/20/2025 – LivaNova was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 12/19/2025 – LivaNova is now covered by analysts at KeyCorp. They set an “overweight” rating and a $81.00 price target on the stock.
• 12/18/2025 – LivaNova is now covered by analysts at KeyCorp. They set an “overweight” rating and a $81.00 price target on the stock.
• 12/17/2025 – LivaNova had its price target raised by analysts at Mizuho from $70.00 to $72.00. They now have an “outperform” rating on the stock.
• 12/16/2025 – LivaNova was given a new $75.00 price target on by analysts at Robert W. Baird.
• 12/15/2025 – LivaNova had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – LivaNova had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/6/2025 – LivaNova was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
• 12/1/2025 – LivaNova had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – LivaNova had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – LivaNova had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – LivaNova had its price target raised by analysts at Robert W. Baird from $63.00 to $70.00. They now have an “outperform” rating on the stock.
• 11/13/2025 – LivaNova had its price target raised by analysts at Mizuho from $65.00 to $70.00. They now have an “outperform” rating on the stock.
• 11/6/2025 – LivaNova had its price target raised by analysts at Robert W. Baird from $61.00 to $63.00. They now have an “outperform” rating on the stock.

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.